A quantitative proteomics screen comparing the phospho-tyrosine (p-Y) content of trastuzumab-sensitive and -resistant breast cancer cell lines identified 12 fold higher levels of p-Y-CDCP1 in resistant cells [20]. This evidence concerns the gene CDCP1 and breast carcinoma.